Arena Pharmaceuticals Inc logo

ARNA - Arena Pharmaceuticals Inc Share Price

$44.54 1.5  3.6%

Last Trade - 27/03/20

Sector
Healthcare
Size
Mid Cap
Market Cap £1.77bn
Enterprise Value £1.21bn
Revenue £661.0m
Position in Universe 1506th / 6320
Bullish
Bearish
Unlock ARNA Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ARNA Revenue Unlock ARNA Revenue

Net Income

ARNA Net Income Unlock ARNA Revenue

Normalised EPS

ARNA Normalised EPS Unlock ARNA Revenue

PE Ratio Range

ARNA PE Ratio Range Unlock ARNA Revenue

Dividend Yield Range

ARNA Dividend Yield Range Unlock ARNA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ARNA EPS Forecasts Unlock ARNA Revenue
Profile Summary

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated April 14, 1997
Public Since July 28, 2000
No. of Shareholders: 83
No. of Employees: 320
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 50,249,149
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ARNA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ARNA
Upcoming Events for ARNA
Wednesday 6th May, 2020 Estimate
Q1 2020 Arena Pharmaceuticals Inc Earnings Release
Friday 12th June, 2020 Estimate
Arena Pharmaceuticals Inc Annual Shareholders Meeting
Wednesday 5th August, 2020 Estimate
Q2 2020 Arena Pharmaceuticals Inc Earnings Release
Similar to ARNA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.